A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy People
NCT05683561 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 6000
Last updated 2023-01-13
Summary
The objective of this study is to evaluate the effectiveness of SCTV01E in healthy people
Conditions
- COVID-19 SARS-CoV-2 Infection
Interventions
- BIOLOGICAL
-
CoronaVac
D0; intramuscular injection
- BIOLOGICAL
-
SCTV01E
D0; intramuscular injection
Sponsors & Collaborators
-
Sinocelltech Ltd.
lead INDUSTRY
Principal Investigators
-
Yu Sun · Sinocelltech Ltd.
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-01-25
- Primary Completion
- 2023-08-25
- Completion
- 2024-08-25
More Related Trials
-
A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults
NCT05037097 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Immunogenicity of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine
NCT05576623 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
NCT07300839 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac or a Formulation of SCB-2019 (COVID-19)
NCT05087368 ·Status: UNKNOWN ·Phase: PHASE2
-
Booster Study of PTX-COVID19-B in Adults Aged 18 Years and Older
NCT05534048 ·Status: UNKNOWN ·Phase: PHASE3
-
Immunogenicity of Heterologous Versus Homologous Prime Boost Schedule With mRNA and Inactivated COVID-19 Vaccines
NCT05668065 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine
NCT05636319 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
An Effectiveness Study of the Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine
NCT04747821 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Safety and Immunogenicity of a Novel Vaccine for Prevention of Covid-19 in Adults Previously Immunized
NCT05016934 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Study to Assess Safety, Reactogenicity and Immunogenicity of the repRNA(QTP104) Vaccine Against SARS-CoV-2(COVID-19)
NCT05876364 ·Status: UNKNOWN ·Phase: PHASE1
-
Clinical Trial of Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults
NCT04962308 ·Status: UNKNOWN ·Phase: PHASE4
-
Study to Assess Safety, Reactogenicity and Immunogenicity of the VACCINE RNA MCTI CIMATEC HDT (HDT-301) Vaccine Against COVID-19
NCT04844268 ·Status: UNKNOWN ·Phase: PHASE1
-
Immunogenicity and Safety of Adjuvanted SCB-2020S Vaccines in Adults
NCT04950751 ·Status: WITHDRAWN ·Phase: PHASE2
-
Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVID-19) Variant in Adults
NCT05029856 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19
NCT04672395 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study)
NCT05057169 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults
NCT04816669 ·Status: COMPLETED ·Phase: PHASE3
-
Phase I Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) (WSK-V102)
NCT05765604 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals
NCT04456595 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination
NCT05911048 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years
NCT07069309 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)
NCT04993365 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Immunogenicity Study of Booster Vaccination With COVID-19 Vaccine (Vero Cell),Inactivated From Different Manufactures for Prevention of COVID-19
NCT05165732 ·Status: SUSPENDED ·Phase: PHASE4
-
Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults
NCT04911790 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Inactivated Vaccine in Healthy Adults Against Coronavirus Disease of 2019 (COVID-19)
NCT05128721 ·Status: UNKNOWN ·Phase: PHASE1